Intellia plots Phase 3 study and a 2026 FDA submission after CRISPR therapy cuts swelling attacks by 98%

Intellia Therapeutics has revealed that a single infusion of its experimental CRISPR therapy, called NTLA-2002, almost entirely eliminated swelling attacks in 10 people with hereditary …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence – Pharmaceutical Technology

Biogen’s acquisition of HI-Bio’s anti-CD38 monoclonal antibody will expand its immunology presence. Image credit: Shutterstock / Tada Images. As Eli Lilly’s Kisunla (donanemab) enters the

July 3, 2024

Obesity in early pregnancy increases long-term risk of venous thromboembolism

Investigated the association between obesity in early pregnancy and long-term post-pregnancy risk of venous thromboembolism.

September 7, 2023

Intuitive’s Q3 sales miss estimates as robot leasing, China demand weigh

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. By the numbers Q3 revenue: $1.74 billion

October 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.